Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma

Epilepsia

Volumn 52, Issue 4, 2011, Pages 657-678

  Löscher, Wolfgang ^a   Schmidt, Dieter ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Epilepsy Research Group   (Germany)

Author keywords

Comparative effectiveness; Drug develop ment; Epilepsy; Pharmacoresistance; Trial design

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOBAZAM; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; HYDROCORTISONE; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGABIDE; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; DEPRESSION; DISEASE DURATION; DRUG DESIGN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; LENNOX GASTAUT SYNDROME; LIVER FAILURE; MONOTHERAPY; MYOCLONUS; MYOCLONUS EPILEPSY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; TERATOGENICITY; VISUAL FIELD DEFECT; WEST SYNDROME;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS;

EID: 79953705357     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03024.x     Document Type: Review

References (136)

1. Andersohn F, Schade R, Willich SN, Garbe E,. (2010) Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 75: 335-340.
2. Anderson RJ,. (2009) The little compound that could: how phenytoin changed drug discovery and development. Mol Interv 9: 208-214.
3. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM,. (2010) Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 363: 542-551.
4. Aronson JK,. (2006) Industry-sponsored clinical research-an editor's view. In, Halkin H, Tal O, (Eds) Patients, physicians, and pharma. The Israel National Institute for Health Policy Research, Haifa, pp. 15-28.
5. Barton ME, Klein BD, Wolf HH, White HS,. (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47: 217-228.
6. Baulac M, Leon T, O'Brien TJ, Whalen E, Barrett J,. (2010) A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 91: 10-19.
7. Beydoun A, Kutluay E,. (2003) Conversion to monotherapy: clinical trials in patients with refractory partial seizures. Neurology 60: S13-S25. (Pubitemid 36736308)
8. Beyenburg S, Stavem K, Schmidt D,. (2010) Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 51: 7-26.
9. Bialer M, White HS,. (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 9: 68-82.
10. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS,. (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83: 1-43.
11. Birbeck GL, Hays RD, Cui X, Vickrey BG,. (2002) Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43: 535-538. (Pubitemid 34533711)
12. Brandt C, Bethmann K, Gastens AM, Löscher W,. (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24: 202-211. (Pubitemid 44416217)
13. Brodie MJ, Perucca E, Ryvlin P, Ben Menachem E, Meencke HJ,. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408. (Pubitemid 46208740)
14. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA,. (2007) Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62: 382-389. (Pubitemid 350105952)
15. Center for Drug Evaluation and Research (CEDR) (FDA). (2010) Available at:.
16. Chadwick D, Privitera M,. (1999) Placebo-controlled studies in neurology: where do they stop? Neurology 52: 682-685. (Pubitemid 29120166)
17. Chen G, Portman R, Ensor CR, Bratton AC Jr,. (1951) The anticonvulsant activity of o-phenyl succinimides. J Pharmacol Exp Ther 103: 54-61.
18. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O,. (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26: 389-395. (Pubitemid 27117815)
19. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G,. (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356: 1638-1642.
20. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P,. (2010) Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51: 958-967.
21. Coatsworth JJ,. (1971) Studies on the clinical effect of marketed antiepileptic drugs. NINDS Monograph 12. US Department of Health and Education, Bethesda, MD.
22. Committee for Proprietary Medicinal Products (CPMP). (2000) Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders (CPMP/EWP/566/98 rev 1), London. Available at:.
23. Cramer JA, Steinborn B, Striano P, Hlinkova L, Bergmann A, Bacos I, Baukens C, Buyle S,. (2010) Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand in press.
24. Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, Gergont A, Kroczka S, Kacinski M,. (2009) Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin Drug Metab Toxicol 5: 131-136.
25. d'Ambrosio R, Miller JW,. (2010) What is an epileptic seizure? Unifying definitions in clinical practice and animal research to develop novel treatments. Epilepsy Curr 10: 61-66.
26. Darke K, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Lux AL, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP,. (2010) Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 95: 382-386.
27. Dichter MA,. (2009) Posttraumatic epilepsy: the challenge of translating discoveries in the laboratory to pathways to a cure. Epilepsia 50 (suppl 2): 41-45.
28. Doughty RN, MacMahon S, Sharpe N,. (1994) Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 23: 814-821. (Pubitemid 24074966)
29. Elger CE, Schmidt D,. (2008) Modern management of epilepsy: a practical approach. Epilepsy Behav 12: 501-539.
30. EMEA. (2001) Note for guidance on choice of control group in clinical trials (CPMP/ICH/364/96). Available at:.
31. EMEA, Committee for Medicinal Products for Human Use (CHMP). (2010) Clinical investigation of medicinal products in the treatment of epileptic disorders (EWP/566/98 Rev. 2). Available at:.
32. Everett GM, Richards RK,. (1944) Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione), Dilantin and phenobarbital. J Pharmacol Exp Ther 81: 402-407.
33. Farooq MU, Bhatt A, Majid A, Gupta R, Khasnis A, Kassab MY,. (2009) Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm 66: 541-561.
34. Faught E, Peters D, Bartolucci A, Moore L, Miller PC,. (1989) Seizures after primary intracerebral hemorrhage. Neurology 39: 1089-1093. (Pubitemid 19217479)
35. Finnerup NB, Grydehoj J, Bing J, Johannesen IL, Biering-Sorensen F, Sindrup SH, Jensen TS,. (2009) Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord 47: 861-867.
36. French JA, England JD,. (2010) Invited article: comparative effectiveness research, evidence-based medicine, and the AAN. Neurology 75: 562-567.
37. French JA, Wang S, Warnock B, Temkin N,. (2010) Historical control monotherapy design in the treatment of epilepsy. Epilepsia 51: 1936-1943.
38. Garattini S, Bertele' V,. (2007) Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370: 1875-1877. (Pubitemid 350180009)
39. Glauser T, Ben Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T,. (2006) ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47: 1094-1120. (Pubitemid 44086745)
40. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S,. (2008) Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70: 1950-1958.
41. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC,. (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362: 790-799.
42. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E,. (1992) ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222: 193-203.
43. Gowers WR,. (1881) Epilepsy and other chronic convulsive diseases: their causes, symptoms, and treatment. Churchill, London.
44. Gram L, Schmidt D,. (1993) Innovative designs of controlled clinical trials in epilepsy. Epilepsia 34 (suppl 7): S1-S6. (Pubitemid 24000778)
45. Hönack D, Löscher W,. (1995) Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36: 763-771.
46. Katz R,. (2006) FDA update. Epilepsy Res 68: 85-94. (Pubitemid 43052791)
47. Kharatishvili I, Pitkänen A,. (2010) Posttraumatic epilepsy. Curr Opin Neurol 23: 183-188.
48. Klitgaard H, Pitkänen A,. (2003) Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 5 (suppl 1): S9-S16. (Pubitemid 36818439)
49. Klitgaard H, Matagne A, Gobert J, Wulfert E,. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353: 191-206. (Pubitemid 28352266)
50. Klitgaard H, Matagne A, Lamberty Y,. (2002) Use of epileptic animals for adverse effect testing. Epilepsy Res 50: 55-65. (Pubitemid 34876586)
51. Krall RL, Penry JK, Kupferberg HJ, Swinyard EA,. (1978a) Antiepileptic drug development: I. History and a program for progress. Epilepsia 19: 393-408.
52. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA,. (1978b) Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 19: 409-428. (Pubitemid 9016848)
53. Kwan P, Brodie MJ,. (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319. (Pubitemid 30075244)
54. Leber PD,. (1989) Hazards of inference: the active control investigation. Epilepsia 30 (Suppl. 1): S57-S63. (Pubitemid 19239014)
55. Lindberger M, Alenius M, Frisén L, Johannessen SI, Larsson S, Malmgren K, Tomson T,. (2000) Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia 41: 1289-1295.
56. Liu JJ, Saltzman JR,. (2009) Refractory gastro-oesophageal reflux disease: diagnosis and management. Drugs 69: 1935-1944.
57. Löscher W,. (1984) Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find Exp Clin Pharmacol 6: 531-547. (Pubitemid 15217360)
58. Löscher W,. (1986) Experimental models for intractable epilepsy in nonprimate animal species. In, Schmidt D, Morselli PL, (Eds) Intractable epilepsy: experimental and clinical aspects. Raven Press, New York, pp. 25-37.
59. Löscher W,. (1997) Animal models of intractable epilepsy. Prog Neurobiol 53: 239-258. (Pubitemid 27436002)
60. Löscher W,. (1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342: 1-13. (Pubitemid 28131339)
61. Löscher W,. (1999a) Animal models of epilepsy and epileptic seizures. In, Eadie MJ, Vajda F, (Eds) Antiepileptic drugs. Handbook of experimental pharmacology. Springer, Berlin, pp. 19-62.
62. Löscher W,. (1999b) Valproate. Birkhäuser, Basel.
63. Löscher W,. (2002a) Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 23: 113-118. (Pubitemid 34185411)
64. Löscher W,. (2002b) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50: 105-123. (Pubitemid 34876591)
65. Löscher W,. (2006) Animal models of drug-refractory epilepsy. In, Pitkänen A, Schwartzkroin PAMSL, (Eds) Models of seizures and epilepsy. Elsevier, Amsterdam, pp. 551-567.
66. Löscher W,. (2009) Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 610: 1-11.
67. Löscher W,. (2010) Inhibition of P-gp: a new therapeutic concept? Epilepsia 51 (suppl 4): 169.
68. Löscher W, Brandt C,. (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 62: 668-700.
69. Löscher W, Hönack D,. (1991) Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol Sci 12: 52.
70. Löscher W, Hönack D,. (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232: 147-158. (Pubitemid 23080189)
71. Löscher W, Köhling R,. (2010) Functional, metabolic, and synaptic changes after seizures as potential targets for antiepileptic therapy. Epilepsy Behav 19: 105-113.
72. Löscher W, Meldrum BS,. (1984) Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed Proc 43: 276-284. (Pubitemid 14185151)
73. Löscher W, Potschka H,. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602. (Pubitemid 41059334)
74. Löscher W, Schmidt D,. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2: 145-181.
75. Löscher W, Schmidt D,. (1994) Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 17: 95-134. (Pubitemid 24076338)
76. Löscher W, Schmidt D,. (2002) New horizons in the development of antiepileptic drugs. Epilepsy Res 50: 3-16. (Pubitemid 34876581)
77. Löscher W, Schmidt D,. (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47: 1253-1284. (Pubitemid 44200405)
78. Löscher W, Jäckel R, Czuczwar SJ,. (1986) Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp Neurol 93: 211-226. (Pubitemid 16059784)
79. Luciano AL, Shorvon S,. (2007) Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62: 375-381. (Pubitemid 350105951)
80. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD,. (2000) Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 48: 833-841.
81. Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR,. (2007) A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 11: 1-134.
82. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB,. (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313: 145-151. (Pubitemid 15047456)
83. Mattson RH, Cramer JA, Collins JF,. (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 327: 765-771.
84. Meldrum BS,. (1997) Identification and preclinical testing of novel antiepileptic compounds. Epilepsia 38: S7-S15. (Pubitemid 27509869)
85. Meldrum B,. (2002) Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res 50: 33-40. (Pubitemid 34876584)
86. Mohanraj R, Brodie MJ,. (2005) Outcomes in newly diagnosed localization-related epilepsies. Seizure 14: 318-323. (Pubitemid 40916315)
87. Mohanraj R, Brodie MJ,. (2007) Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 115: 204-208. (Pubitemid 46219215)
88. Mula M, Sander JW,. (2007) Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30: 555-567. (Pubitemid 47037315)
89. Perucca E,. (2008) Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 22: 917-938.
90. Perucca E,. (2010) When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia 51: 1933-1935.
91. Perucca E, Tomson T,. (1999) Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 33: 247-262. (Pubitemid 29143361)
92. Perucca E, French J, Bialer M,. (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6: 793-804. (Pubitemid 47243712)
93. Pitkänen A,. (2010) Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia 51 (suppl 3): 2-17.
94. Putnam TJ, Merritt HH,. (1937) Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85: 525-526.
95. Rakhade SN, Jensen FE,. (2009) Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 5: 380-391.
96. Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J,; for the CAPSS-272 Study Group. (2010) Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 51: 1970-1977.
97. Remy S, Beck H,. (2006) Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129: 18-35. (Pubitemid 43063756)
98. Rogawski MA, Bazil CW,. (2008) New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 8: 345-352.
99. Rogawski MA, Johnson MR,. (2008) Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 8: 127-130.
100. Rogawski MA, Löscher W,. (2004a) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5: 553-564. (Pubitemid 38868551)
101. Rogawski MA, Löscher W,. (2004b) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10: 685-692. (Pubitemid 38937632)
102. Rogawski MA, Yamaguchi S, Jones SM, Rice KC, Thurkauf A, Monn JA,. (1991) Anticonvulsant activity of the low-affinity uncompetitive N-methyl-d-aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10- imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J Pharmacol Exp Ther 259: 30-37.
103. Saetre E, Perucca E, Isojärvi Y, Gjerstad L,; on behalf of the LAM 40089 Study Group. (2007) An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia, 48: 1292-1302. (Pubitemid 47063092)
104. Sake J-K, Hebert D, Doty P, Zackheim J, Eggert-Formella A, Davies K, Isojärvi J,. (2010) A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 24: 1055-1068.
105. Sato M, Racine RJ, McIntyre DC,. (1990) Kindling: basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol 76: 459-472. (Pubitemid 20370128)
106. Schiller Y, Najjar Y,. (2008) Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 70: 54-65.
107. Schmidt D,. (1983) Single drug therapy for intractable epilepsy. J Neurol 229: 221-226. (Pubitemid 13056530)
108. Schmidt D,. (2009) Drug treatment of epilepsy: options and limitations. Epilepsy Behav 15: 56-65.
109. Schmidt D,. (2011) Efficacy of new antiepileptic drugs. Epilepsy Curr in press.
110. Schmidt D, Beyenburg S,. (2009) Antiepileptic drugs. In, Aronson JK, (Ed.) Side effects of drugs. Annual 31. Elsevier, Amsterdam, pp. 105-148.
111. Schmidt D, Löscher W,. (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46: 858-877. (Pubitemid 40847354)
112. Schmidt D, Löscher W,. (2009) New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr 9: 47-52.
113. Sharief M, Viteri C, Ben Menachem E, Weber M, Reife R, Pledger G, Karim R,. (1996) Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25: 217-224. (Pubitemid 26394543)
114. Shorvon SD,. (2009a) Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 50 (suppl 3): 69-92.
115. Shorvon SD,. (2009b) Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 50 (suppl 3): 93-130.
116. Sillanpää M, Schmidt D,. (2009) Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 132: 989-998.
117. Sisodiya SM,. (2003) Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16: 197-201. (Pubitemid 36521207)
118. Smith M, Wilcox KS, White HS,. (2007) Discovery of antiepileptic drugs. Neurotherapeutics 4: 12-17. (Pubitemid 46107328)
119. Stables JP, Bertram EH, White HS, Coulter DA, Dichter MA, Jacobs MP, Löscher W, Lowenstein DH, Moshe SL, Noebels JL, Davis M,. (2002) Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 43: 1410-1420. (Pubitemid 35365001)
120. Sun L, Lin SS,. (2000) The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia 41: 263-270. (Pubitemid 30134280)
121. Swinyard EA,. (1949) Laboratory assay of clinically effective antiepileptic drugs. J Am Pharm Assoc Am Pharm Assoc 38: 201-204.
122. Swinyard EA, Brown WC, Goodman LS,. (1952) Comparative assay of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106: 319-330.
123. Temkin NR,. (2009) Preventing and treating posttraumatic seizures: the human experience. Epilepsia 50 (suppl 2): 10-13.
124. Toman JE, Swinyard EA, Goodman LS,. (1946) Properties of maximal seizures, and their alteration by anticonvulsant drugs and other agents. J Neurophysiol 9: 231-239.
125. Tomson T, Battino D,. (2009) Teratogenic effects of antiepileptic medications. Neurol Clin 27: 993-1002.
126. US Food and Drug Administration. (2008) FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications. Available at:.
127. Varming T,. (1998) ADCI National Institutes of Health. IDrugs 1: 339-343. (Pubitemid 128751610)
128. Vigevano F, Cilio MR,. (1997) Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 38: 1270-1274. (Pubitemid 28007515)
129. White HS,. (1997) Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 38: S9-S17. (Pubitemid 27150607)
130. White HS,. (2003) Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 44 (suppl 7): 2-8. (Pubitemid 37100022)
131. White HS, Woodhead JH, Franklin MR, Swinyard EA, Wolf HH,. (1995) Experimental selection, quantification, and evaluation of antiepileptic drugs. In, Levy RH, Mattson RH, Meldrum BS, (Eds) Antiepileptic drugs, 4th ed. Raven Press, New York, pp. 99-110.
132. White HS, Wolf HH, Woodhead JH, Kupferberg HJ,. (1998) The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy. Adv Neurol 76: 29-39.
133. White HS, Smith-Yockman M, Srivastava A, Wilcox KS,. (2006) Therapeutic assays for the identification and characterization of antiepileptic and antiepileptogenic drugs. In, Pitkänen A, Schwartzkroin PA, Moshé SL, (Eds) Models of seizures and epilepsy. Elsevier, Amsterdam, pp. 539-549.
134. White HS, Porter RJ, Kupferberg HJ,. (2008) Screening of new compounds and the role of the pharmaceutical industry. In, Engel JJ, Pedley TA, (Eds) Epilepsy. A comprehensive textbook, 2nd ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, pp. 1469-1485.
135. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C,. (2005) Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 9: 1-157, iii-iv.
136. Willmore LJ, Abelson MB, Ben Menachem E, Pellock JM, Shields WD,. (2009) Vigabatrin: 2008 update. Epilepsia 50: 163-173.